Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN - A randomized, phase III study

Journal of Clinical Oncology

Volumn 32, Issue 19, 2014, Pages 2039-2049

  Satoh, Taroh ^a   Doi, Toshihiko ^b   Ohtsu, Atsushi ^b   Tsuji, Akihito ^c   Omuro, Yasushi ^d   Mukaiyama, Akihira ^e   Kobayashi, Mikiro ^e   Miwa, Hiroto ^f   Xu, Rui Hua ^g   Sun, Guo Ping ^h   Xu, Jian Ming ⁱ   Wang, Jin Wan ^j   Li, Jin ^k   Qin, Shu Kui ^l   Feng, Ji Feng ^m   Chung, Hyun Cheol ⁿ   Bang, Yung Jue ^o   Chung, Ik Joo ^p   Yeh, Kun Huei ^q  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c Kochi Health Sciences Center   (India)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e Development and Medical Affairs Division   (Japan)

^f HYOGO COLLEGE OF MEDICINE   (Japan)

^g SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^h ANHUI MEDICAL UNIVERSITY   (China)

ⁱ 307 Hospital of the People's Liberation Army   (China)

^j CANCER HOSPITAL   (China)

^k FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^l The 81 Hospital of Peoples Liberation Army   (China)

^m JIANGSU CANCER HOSPITAL   (China)

ⁿ Yonsei University College of Medicine   (South Korea)

^o Seoul National University College of Medicine   (South Korea)

^p Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^q NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASIAN; ASTHENIA; BACKACHE; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRECTOMY; HEART ARREST; HEART LEFT VENTRICLE FAILURE; HUMAN; INTERSTITIAL LUNG DISEASE; LEUKOCYTE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SENSORY NEUROPATHY; STOMACH CANCER; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PACLITAXEL; PILOT PROJECTS; QUINAZOLINES; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84905566147     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.6136     Document Type: Article

References (27)

1. Jemal A, Center MM, DeSantis C, et al: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907, 2010
2. Ferlay J, Shin HR, Bray F, et al: GLOBOCAN 2008 (version 2.0): Cancer incidence and mortality worldwide - IARC CancerBase No. 10: International Agency for Research on Cancer. http://globocan.iarc.fr
3. American Cancer Society: Survival rates for stomach cancer by stage, 2013. http://www.cancer.org/cancer/stomachcancer/detailedguide/stomach-cancer- survival-rates
4. Cancer Research UK: Stomach cancer survival statistics, 2012. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/stomach/survival/ stomach-cancer-survival-statistics
5. Inoue M, Tsugane S: Epidemiology of gastric cancer in Japan. Postgrad Med J 81:419-424, 2005 (Pubitemid 41002579)
6. Jung KW, Park S, Kong HJ, et al: Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2008. Cancer Res Treat 43:1-11, 2011
7. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46, 2008
8. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 9:215-221, 2008
9. Egawa T, Kubota T, Nagashima A, et al: Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer [in Japanese]. Gan To Kagaku Ryoho 31:877-881, 2004
10. Hironaka S, Zenda S, Boku N, et al: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9:14-18, 2006
11. Kodera Y, Ito S, Mochizuki Y, et al: A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 27:2667-2671, 2007 (Pubitemid 47227980)
12. Ueda S, Hironaka S, Yasui H, et al: Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. J Clin Oncol 30:239s, 2012 (suppl; abstr 4002)
13. Takehana T, Kunitomo K, Kono K, et al: Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int J Cancer 98:833-837, 2002 (Pubitemid 34286677)
14. Park DI, Yun JW, Park JH, et al: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51:1371-1379, 2006 (Pubitemid 44315804)
15. Yano T, Doi T, Ohtsu A, et al: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15:65-71, 2006
16. Barros-Silva JD, Leitão D, Afonso L, et al: Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 100:487-493, 2009
17. Tsapralis D, Panayiotides I, Peros G, et al: Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World J Gastroenterol 18:150-155, 2012
18. Halon A, Donizy P, Biecek P, et al: HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. ScientificWorldJournal 2012:941259, 2012
19. Huang JX, Zhao K, Lin M, et al: HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. Oncol Lett 6:13-18, 2013
20. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
21. Electronic Medicines Compendium: Summary of product characteristics (Tyverb), 2013. http://www.medicines.org.uk/EMC/medicine/20929/SPC/Tyverb
22. Kang JH, Lee SI, Lim do H, et al: Salvage chemotherapy for pretreated gastric cancer: A randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513-1518, 2012
23. Thuss-Patience PC, Kretzschmar A, Bichev D, et al: Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47:2306-2314, 2011
24. Ford H, Marshall A, Wadsley J, et al: Cougar-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. J Clin Oncol 30, 2012 (suppl 34; abstr LBA4)
25. Hironaka S, Ueda S, Yasui H, et al: Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31:4438-4444, 2013
26. Burris HA 3rd, Hurwitz HI, Dees EC, et al: Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23:5305-5313, 2005 (Pubitemid 46206984)
27. Guan Z, Xu B, DeSilvio ML, et al: Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 31:1947-1953, 2013